A carregar...
Potential mechanisms of resistance to venetoclax and strategies to circumvent it
BACKGROUND: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It is also being evaluated in numerous clinical trials for treating pa...
Na minha lista:
| Publicado no: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5457565/ https://ncbi.nlm.nih.gov/pubmed/28578655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3383-5 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|